Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drug Classes and Categories01:25

Drug Classes and Categories

Drugs can be classified according to their chemical composition or their intended therapeutic application. For instance, anti-infective agents that possess the ability to eliminate pathogens or suppress their growth and reproduction can be grouped based on the organisms they target or their chemical structure. Furthermore, drugs can be divided into prescription, nonprescription, or controlled substances. Prescription medications, such as antibiotics, require oversight from a licensed healthcare...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Creativity and Ideation in Dental Education: Sip, Stain, and Glaze.

Journal of dental education·2025
Same author

Fluvastatin Converts Human Macrophages into Foam Cells with Increased Inflammatory Response to Inactivated <i>Mycobacterium tuberculosis H37Ra</i>.

Cells·2024
Same author

Interrogating the Role of Human Rights in Remedying Global Inequities in Access to COVID-19 Vaccines.

Health and human rights·2022
Same author

How can health technology assessment support our response to public health emergencies?

Health research policy and systems·2022
Same author

What Can We Learn From Others to Develop a Regional Centre for Infectious Diseases in ASEAN? Comment on "Operationalising Regional Cooperation for Infectious Disease Control: A Scoping Review of Regional Disease Control Bodies and Networks".

International journal of health policy and management·2022
Same author

StopWatch: Pilot study for an Apple Watch application for youth with ADHD.

Digital health·2021

関連する実験動画

Updated: Jun 26, 2026

Optogenetic Functional MRI
06:06

Optogenetic Functional MRI

Published on: April 19, 2016

貿易,TRIPS,医薬品について

Richard D Smith1, Carlos Correa, Cecilia Oh

  • 1Health Policy Unit, Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK.

Lancet (London, England)
|January 27, 2009
PubMed
まとめ

知的財産権の貿易関連の側面に関する協定 (TRIPS) は,先進国に利益をもたらしたが,発展途上国に利益をもたらさなかった. 医薬品貿易と医薬品へのアクセスの不平等は問題であり,交渉戦略が必要であることを強調しています.

科学分野:

  • 知的財産権法 知的財産権法 知的財産権法
  • 国際貿易法 国際貿易法
  • 医薬品経済学 医薬品経済学

背景:

  • 知的財産権の貿易関連側面に関する協定 (TRIPS) は,グローバルな知的財産権 (IP) 基準を確立しました.
  • TRIPSは知的財産権を大幅に拡大し,製薬業界と先進経済に利益をもたらしました.
  • 開発途上国は,特に医薬品貿易に関するTRIPSの経済的利益に疑問を投げかけています.

研究 の 目的:

  • TRIPSが輸出の増加を通じて開発途上国にとって経済的利益をもたらしたかどうかを評価する.
  • TRIPSとTRIPS+の条項が,医薬品取引と医薬品へのアクセスに及ぼす影響を分析する.
  • TRIPSの枠組みの中で,保健コミュニティのための交渉戦略を特定する.

主な方法:

  • 世界保健医療貿易における医薬品の重要性を検討する.
  • 二国間自由貿易協定のTRIPS要件,影響,およびTRIPSプラス条項の分析.
  • 特許薬に関する先進国と開発途上国の間の貿易パターンの検討.

主要な成果:

  • TRIPSは,開発途上国にとって実質的な輸出利益をもたらしていない.
  • 医薬品の貿易は,主に先進国において増加した.

さらに関連する動画

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
12:17

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions

Published on: May 8, 2017

Radiosynthesis of 1-(2-[18F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol
08:33

Radiosynthesis of 1-(2-[18F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol

Published on: September 21, 2021

関連する実験動画

Last Updated: Jun 26, 2026

Optogenetic Functional MRI
06:06

Optogenetic Functional MRI

Published on: April 19, 2016

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
12:17

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions

Published on: May 8, 2017

Radiosynthesis of 1-(2-[18F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol
08:33

Radiosynthesis of 1-(2-[18F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol

Published on: September 21, 2021

  • 不平等な貿易動態とTRIPS-plusの条項は,開発途上国における医薬品へのアクセス問題を悪化させる.
  • 結論:

    • 開発途上国は,医薬品の輸出の増加という点で,TRIPSから大きな利益を得ていない.
    • TRIPSプラス条項は,多くの国がTRIPSの柔軟性を利用していないにもかかわらず,医薬品へのアクセスを悪化させます.
    • 医療界は,TRIPSを有利に活用するために交渉の選択肢を探求する必要があります.